Organo-Fluorine Compounds as Artificial Blood Substitute by Agarwal, Vipin Kumar
ORGANO-FLUORINE COMPOUNDS AS ARTIFICIAL BLOOD SUBSTITUTE 
Centrar Drug Research Institute, Lucknow-226001 
. (Received 19 February 1979; revised 19 June 1979) 
The rate of fluoro-carbon compounds as artificial substitute for blood has been discussed. Blood is a com- 
plicated body fluid. At first glance it seems impossible that such a complicated body fluid can be replaced by 
artificial synthesized fluids or any substitute for this can be synthesized. Fluoro-carbon compounds however 
have advanced research in this area because a number of fluoro-carbon compounds have been found to be 
highly inert and have high solubility for O,/CO, and are able to transport O,/CO, in vivo. 
A number of fluorinating agents and processes are known for synthesis of fluoro-carbon compounds, 
but the following three methods are important I,,. 
Direct Fluorination with fluorine gas. A stream of fluorine gas diluted with nitrogen is reacted with 
the compound to be fluorinated at temperature about 130-300°C. Disadvantages of the procedure is that 
the reaction is highly exothermic and number of fragmented and partially fluorinated compounds are 
formed as by-products. 
Cobalt tr$uoride fluorination. In this msehod vapours of the compound to be fluorinated are diluted 
with nitrogen and reacted with cobalt trifluoride between 200-250°C. Reaction is less exothermic as com- 
pared to first one, but partially fluorinated compounds are produced as reaction by-products. 
Electrofiorination method. This is the method most commonly used. It involves electrolysis of the 
organic compounds in anhydrous hydrofluoric acid. 
Fluoro-carbon compounds are colou_rless, dense and al;parently non-toxic liquids, having very low 
surface energies3, low boiling points, etc. They have much lower surface tension than the corresponding 
hydrocarbon$. They are very poor solvents and are insoluble in water and alcohols. They show high solu- 
bility for 0 2 ,  N2, COz and inert gases. It is the high solubility of 0, in fluoro-carbon compound that 
has made FC-80, a fluoro-carbon compound, so useful in liquid breathing experiments. 
Another unique property of organo-fluorine compounds is their chemical and thermal stability. The 
factors reqponsible are (1) C-F bond strength is 116 K, cal/mol. (2) shielding effect from the high electro 
negativity of the fluorine atoms. They are unaffected by boiling with conc. nitric and sulfuric acid and 
aqueous alkali. They.react with H,, Br, and C12 only under pyrolytic conditions of 700°C or above. Cer- 
tqin other type of compounds having high solubility for 02/C04 have also been studied for this purpose 
such as chelating agents of Fe and C03. 
The term fluoro-carbon ha6 wide meaning. Fluoro-carbon compounds used as artificial blood substi- , 
tute can be designated as perfluorinated carbon compoundsa. These are the fluoro-carbon compounds in 
which all the H atoms have been replaced-by fluorine atom i.e. these have neither have H nor other halogen 
except the fluorine, although certain exceptions are there. 
These liquid perfluoro-carbon-compounds cannot be used as such to substitute the blood as they cannot . 
transport necessary water soluble salts and other metabolites i.e. they are unable to perform the function of 
blood plasma. They are used as substitute for erythrocytes. 
Certain important properties which make these compounds useful as artificial blood erythrocytes are : 
Eficient O$COz transport. Excellent 02/C02 solubility of perfluoro-carbon compounds has made 
them useful for transporting Oz/COp in vivo. Certain perfluoro-carbon compounds have been found to 
01 
DEP. SCI. J., VOL. 30, JANUARY 198Q - 
have even higher solubility for O2 as compared to the natural blood eqthrocytes for example FC-80 has 
about 10% more solubility of 0 , .  Experimental studies have, however, s h w n  that capacity of artificial 
erythrocytes to deliver 0, is less as compared to the natural one5. It is bemuse the state in which 0, is 
present in the two is different. In natural erythrocytes 0, forms a stable but dissociable complex with 
haemoglobin while in parfluoro-carbon-compounds O2 is encapsulated within the ahin film of perfluoro- 
carbon compound. However, the solubility of 0, is. sufficient to perform the function of erythrocytes. 
Search of new compounds with even more solubility of 02 may be more advantageous. 
Biological inertness. Biological inertness is an essential requirement for perfluoro-carbon compounds 
to be used as artificial ertythrocytes. The higher the inertness of a compound the lesser will be ik toxicity 
in the living system. Highly fluorinated and naturated compounds are found to be more inert6. Introduc- 
tion of unsaturation 7,8 or other substitution such as methylation increases the toxicity of these compowds. 
Even the substitution of other halogens has adverse effect. Inertness of these compounds for blood c o w  
ponents is an additional advantage because in number of cases these artificial substitutes are used alongwith 
natural blood, such as oxygenation of blood through artificial erythrocytes~'l9 Two factors which faci- 
litate the blood oxygenation are (i) High solubility of CO,/O, in psrfluorinated compounds, (ii) High 
pressure gradient between the blood and liquid membrane of perfluorinated compounds encapsul- 
ating O2 gas11 helps the diffusion of 02 through the membrane to the blood. 
Studies on interaction of fluoro-carbon compounds with blood in vivo as well as in vitro showed no 
significant alterations in the chemical composition of blood except some change in the coagulation factors5'1'. 
It has been reported that the presence of inert particulate hatter in the blood stream also led to agllutination 
of platelets12 and the formation of pulmonary amboli and thrombi. Thus, although it is established that 
perfluoro-carbon compounds transport 0 , / C 0 2  in vivo, but their presence in considerable amount in 
blood usually causes unwanted phenomenon and death and thus they do not behave as completely inert. 
As described earlier, perfluoro-carbon compounds have very low surface tension and hence unusul surface 
properties. As the surface energy of the liquid perfluoro compound3 is very low the dispersed particles hav- 
ing large surface area interact with the substances involved in the the blood coagulation. 
Experiments carried out on the cause of death by the use of fluoro-carbons ruled out13 t~o'~ossibi1ities 
viz. (i) mechanical blocking by fluoro-carbons. (ii) release of histamine and serotonin. 
Death due to agglutination of blood platelets was supported by the experiments carried out on frogs. 
As there are no platelets in frogs they survived after inf'usion of these artificial substitutesl3. Death could 
also occur due to intravascular fibrin formation which is accompanied by a decrease in concentration of 
platelets. Experimental studies carried out on rabbits by infusion of the perfluoro-carbon compounds 
gave sufficient deviations in concentration of coagulation factor X, XI and XI1 from the normal. 
Low Vapour pressure. Highly fluorinated compounds usually have low boiling points i.e. very high 
vapour pressure, which causes a great difficulty in u$i&g these compounds as blood substitutes because high 
volatality of these compounds interferes with the respiration and causes pulmonary gas embolism which 
can be observed by seeing the expanded lungs14. Perfluoro-octane and perfluorobutyl tetrahydrofuran 
have high vapour pressure, 50 and 51 respectively at body-temperature (37.5" C) and they caused death 
of warm-blooded animals when administered as intravenous emulsionst4. This factor eliminated a number 
ofiperfluoro-carbon compounds to be used for this purpose. Compounds with lower vapour pressure proved 
successful for example perfluoro-decalin (V.  P. 14 at 37.5' C) and perfluorotributylamine having (V.P. 
2.5 at 37.5"C) gave good results. It might be possible that certain perfluoro-compounds having other re- 
quired properties can be used by reducing their vapour pressure. V. P. of perfluoro-carbon compounds 
can be decreased by increasing their molecular weight by methods such as halogenation, methylation, etc. 
For example perfluoro-octane has vapour pressure 50 at normal body temperature while its brominated 
product perfluoro-octyl bromide has vapour pressure of only 14. Similarly perfluoro-decalin V. P. 14 at 
37" C on methylation gives perfluoro-methyl-decalin having vapour pressure of only 5 at 37' C. 
But it was observed that these substitutions increase their toxicity. For example, perfluoro-octane 3 day 
LD 50 is about 30 ml/kg, while perfluoro-octyl-bromide has 3 day LD 59 about 150 ml/kg. 
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. Disptrsibility to form Emulsion. As discussed earlier, these perfluoro-carbon compounds cannot be 
used as such to substitute the Blood, because of their inability to perform the function of blood plasmas. 
They are used as substitute to erythrocytes. It is necessary to prepare their emulsion before they can be used 
as artificial blood substitutes. Emulsion15 consists of two immiscible liquids, one is present in the form of 
small droplets as internal phase also called as discontinuous phase, into the other, known as continuous or 
external phase16. Perfluoro-carbon compounds are present in the form of small droplets as internal phase. 
While the other that is external phase is aq. saline solution. In order to get a stable emulsion of these two 
immiscible liquids some stabilising agent is necessary which is known as emulsifying agent. An emulsifier 
may be defined as a chemical compound that reduces the interfacial tension between two dissimilar surfaces, 
thereby allowing a large increase in interfacial area. We can classify emulsions in two types depending on 
the size of droplets (i) microemulsion-particle size more than 1 pm but usually less than 1-2 pm and it 
is transparent (ii) macroemulsion-it is on opaque emulsion having particles of size about 2 pm as in 
case of natural erythrocytes. Erythrocytes are approximately 8-10 pm in diameter. 
Important requirements of an emulsifier to be used for synthetic blood purpose are17 : 
(a) It should be non-toxic, that means, it should not be toxic to living system and it must not pro- 
duce any toxic substance on aging in the body. 
(b) It must be stable in aqueous solution at pH 7.4 and in physiological saline. 
(c) It must be chemically inert or rather it should not interact with the components of the blood to 
disturb in its normal functions. 
(d) It must be stable to 02/C02 and 
(e) It must be readily excreted from the body. 
Egg phospholipids14, because of their wide acceptance as intravascular lipid emulsifier and their ability 
to emulsify perfluoro-decalins, have been accepted as good emulsifiers for perfluorinated organo-compounds. 
Another good emulsifier is Pluronic18 F 68, because of its ability to reproduce the oncotic pressure similar 
to that provided by blood proteins. Further the size of droplets in the emulsion also plays an important 
role. Fine emulsions have the advantage over the coarse, because the half life span of blood level of fine 
emulsion is far larger than that of coarse emulsion. 
Emulsifkation is usually carried out by sonication. But the formation of emulsion by sonication led 
to the generation of fluoride ions13. This difficulty was overcome by providing CO:, atmosphere which 
has a number of advantage@'. 
(a) It provides an inert atmosphere and therefore diminishes possible oxidation of emulsifier. 
(b) Being very soluble in the fluorocarbons it facilitates their emulsification perhaps by enhancing 
cavitation. 
(c) Most important function of COz is to prevent the generation of fluoride ions. It reduces the gene- 
ration of fluoride ions by about 1/10 as compared to C02 free atmosphere. 
Finally an important requirement in using these perfluorinated carbon compounds as artificial erythro- 
cytes is their elimination from the body. It is seen that certain perfluorinated-carbon-compounds remain 
attached to the liver of the animal for many years, rather for life long. Thus the perfluorinated compounds 
which remain intact in the tissue cannot be used even as temporary substitutes. Taking this criterion FC-47, 
E'C-43, PIB, PIID and Freon E series and number of others have been eliminated from &her c~~iderationl4. 
A very successful perfluorinated carbon compound, perfluorotributyl amine20 which has all the important 
requirements and forms a stable emulsion with pluronic-polyol had to be eliminated because of its retention 
in the body tissue for a very long time, may be even life'long. Thus several perfluorinated carbon corn- 
pounds have to be eliminated because of their lacking in one or other property. - 
Studies have been carried out on total replacement of natural blood by artificial prepmatioh. A typical 
composition of the artificial blood currently being used for complete blood replacement studies is as follows :2o 
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Fluora=carbon FC-47 12 ml 
Pluronic .polyo1 + 2 . 5 g  ' 
Hydroxy ethyl starch 3 .0  g 
Glucose 0.1 g 
KC1 32 mg 
Mg Cl2 7 mg 
NaH2P0, 9 .6  mg 
NaCl 54 mg 
CaC12 18 mg 
Na2C0, to pH 7.44 
H20  to 100 ml 
Mixture is gassed with 95 % 0, and ' 5 % CO2 and final pH was adjusted to 7.4 .  Certain antibiotics such 
as streptomycin, penicillin and-phenol red may be added. The oncotic pressure was adjusted by pluronic 
polyol and hydroxy ethyl'starch equals to that of rat serum. Emubification was done by Sonkition after 
providing C 0 2  atmosphere, in order to reduce thefluo~ide ions generation. The only disadvantage of this 
preparation was the retention of PC-47 in the body tissue. It was suggested that certain changes in the above 
formulation and decrease in the size of perfluaro-carbon-compound may be helpful. In the above sample 
particles diameter was between 1 .0 pm to 1 . 5  pm. But the retention of its perfluorinated compound was 
not found to produce any abnormality,. however long retention in the tissue may produce certain 
abnormalities. 
Another important compound perfluorodecalin has the advantage over FC-47 in that it is eliminated 
very soon from the tissue but on the other hand it is very difficult to $repare it$ stable emulsion. Egg phos: 
pholipid was used for preparing its emulsion2l. An emulsion of 25 % wtlvol perfluorodecalin, with 4 % 
phospholipid was prepared. It contained average size particles of 1 .25 pm containing about 30 % of 
particleslarger than 2 pm. It was not found stable at body temperature. If parfluorodecalin can be emulsi- 
fied it will be the most successful compound of all the known compounds till today. 
R E F E R E N C E S  
1. DALE, D. D. & DEWEY, G .  H., Federation Proceedings; 34, (1975), 1444--48. 
2. JOHN, W. SAROENT & RAYMOND, J. SEFFE., Federation Proceedings., 29, (1?70), 1699-1703. 
3. BALDWIN, J. E,, Federation Proceedings., 34, (1975). 
4. C~ARK;L. C. JR:, B E C A ~ N I ,  F.  KAPLAN, S., OBROCK, V., GOHEN. D. & BECKEN C., Science., 181 (1973), 680. 
5. HENRY, A. SLOVITER, Federation Proceedings., 34 (1975),1484-87. 
6. CLAYTON, J. W. JR.. Fluorrhe Chem Rev., 1 (1967), 197. 
7. CLAYTON, J. W. JR., .I. Occupational Med., 4 (1962), 262. 
8. WARITZ, R:S,, U. S. Nat. Tech. Inform. Serv., A. D. Rep. No. (1971). 
9. WALLACE, H. W. & ASHER, W. J., A New Approach-Tran?. Am Spc., 19, (1973), 80. 
10. WALLACE, H. W., ASHER, W. J., ZUBROW, M. T., STEIN T. P. & BROOKS, H., J. Thorac. Cardiovasc Surg., 66 (1973), 
887. - .  
11. WALLACE, H: W., STEIN, T. P. & A S H ~ ,  W .  J . ,  Federation Proceedings., 34 (1975), 1506-9. 
12. STEHBEN, W. E. &@LOREY, H. W., Quart: J.  Exptl. Physiol., 45 (1950), 251. 
13. HENRY, H. S L Q V ~ ,  e ~ . ~ l . ,  Federation Proceediws:, 29 (1970), 1755-57. 
14. L E L A ~ ,  C.CLARK, et.al., Fedration Proceedings., M (1975), 1468-76. 
15. ~ C H E R ,  P., 'Emulsions : Theory iind Practice,' 2nd Ed., (Reinhold, New York), 1965. 
16. GRIFFIN, W. C. In., 'Encyclopedia ~f Chemical Technology,' 2nd Ed., edited by R. E. KIRK & D. F. OTHMER; (Wiley, New 
York, 1975, p, 117. 
17. Invlw, R. SCWlilWgA.. Federation Proceedings., 34 (1975), 1449-53. 
18. HYMES, A. C.;SAFAVW, M. H., ARBULU, A. & BAULE, P., J. Thorac. Cardiv. Surg., 56 (1968), 16, 
19. MAIJGH, T. H., ~cience.,fl611973), 669. 
20. ROBERT, P. GAYER, Federation Proceedings., 34 (1975), 1499. 
, 21. ~AXT.JMASA. YOKOYAMA K., et. al., Federation Procee&ngs., 34 (1975), 1478-83, - 
54 
7s-~ssi4&my400-7-3-80-G~P8 
. 
